Remove 2014 Remove Compliance Remove World Health
article thumbnail

SQA Regulatory Surveillance Summary for May and June 2024

SQA

Level 2: When a simplified analysis of the EFRA inspection report is performed to evaluate compliance with the GMP requirements and may be adopted unilaterally by ANVISA. The classification criteria include: Serious deficiencies: Typically linked to non-compliance with critical items. Major deficiencies: Associated with major items.

FDA 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – May And June

SQA

The rules also cover other services that perform activities related to clinical analysis examinations, such as isolated (private) offices and pharmacies, which are considered health services since the publication of Law 13.021/2014. Description of appropriate compliance times for GMP regulations. Floor 9, No. 381(a)(3).

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary 3 | Monthly Update 2021

SQA

The European Medical Device Coordination Group (MDCG) has issued a new document covering key questions and considerations regarding custom-made medical devices in the context of Medical Devices Regulation (MDR) compliance. These missions will allow the Commission to identify, and, if necessary, correct any non-compliance or weaknesses.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

China’s Center for Medical Device Evaluation (CMDE) Update Compliance Guidelines and Recommended Paths for Clinical Evaluation Paths for Certain Medical Devices, 25 July 2022. 29 of 2022 , Technical Guidelines for Compliance with the Essential Principles of Medical Device Safety and Performance. 26 of 2014. CMDE Announcement No.

FDA 40
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – May

SQA

536/2014 on Clinical Trials, which will replace EU Annex 13. 536/2014 on Clinical Trials replacing EU Annex 13. World Health Organization (WHO). A new Annex 16 on the Certification by the Authorized Person and Batch Release. PIC/S Annex 13 has been revised based on EC Regulation No. Therapeutic Goods Administration (TGA).

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

After receiving complaints, ANVSA performed joint inspections with local health surveillance agencies. The reported irregularities and the manufacturing conditions of the products, that is, compliance with Good Manufacturing Practices, were verified on the spot.

FDA 52